Add-on Acquisition • Life Science

Calliditas Acquires Genkyotex SA

On August 13, 2020, Calliditas acquired life science company Genkyotex SA for 20M USD

Acquisition Context

This is Calliditas’ 1st transaction in the Life Science sector.
This is Calliditas’ largest (disclosed) transaction.
This is Calliditas’ 1st transaction in Switzerland.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	August 13, 2020
Target	Genkyotex SA
Sector	Life Science
Buyer(s)	Calliditas
Deal Type	Add-on Acquisition
Deal Value	20M USD
Advisor(s)	Stifel (Financial) McDermott Will & Emery (Legal)

Target Company

Genkyotex SA

Geneva, Switzerland

Genkyotex SA is a specialty pharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Genkyotex was founded in 2006 and is based in Geneva, Switzerland.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Calliditas

Stockholm, Sweden

Category	Company
Founded	2004
Sector	Life Science
Employees	222
Revenue	1.2B SEK (2023)

DESCRIPTION

Calliditas is a specialty pharmaceutical company developing high-value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products. Calliditas was formed in 2004 and is based in Stockholm, Sweden.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Switzerland	1 of 1
Year: 2020	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Switzerland M&A - 2020 M&A